ppi-0903 has been researched along with Meningitis--Pneumococcal* in 2 studies
2 other study(ies) available for ppi-0903 and Meningitis--Pneumococcal
| Article | Year |
|---|---|
Ceftaroline versus standard therapy for pneumococcal meningitis in critically ill patients.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Critical Illness; Humans; Meningitis, Pneumococcal | 2022 |
Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.
Five cases of bacterial meningitis treated with ceftaroline (4 Streptococcus pneumoniae and 1 Staphylococcus aureus) are summarized here. The pharmacodynamics of human cathelicidin LL-37 and ceftaroline were evaluated against S. pneumoniae. Patients who received ceftaroline 600 mg every 8 h (q8h) (1 S. aureus and 3 S. pneumoniae) were successfully treated; treatment failed in 1 patient with S. pneumoniae who received 600 mg q12h. Ceftaroline increased the negative surface charge and sensitized S. pneumoniae to killing by LL-37, a peptide implicated in blood-brain barrier defense. Topics: Adult; Aged; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Ceftaroline; Cephalosporins; Cytochromes c; Drug Interactions; Female; Humans; Male; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Middle Aged; Streptococcus pneumoniae; Survival Analysis | 2015 |